simedice

Simedice was registered and established in Zhengzhou, China, in October 2018, with a registered capital of 50 million yuan. Simedice is a Sino-US joint venture invested and controlled by Shanghai Haohai Pharmaceutical Development Technology Co., Ltd., a subsidiary of Shanghai Haohai Biotechnology Co., Ltd., which is listed on both the STAR Market in China and in Hong Kong. Simedice is a comprehensive high-tech enterprise initiated by an American technical management team, integrating research and development, production, and sales. The company utilizes advanced American technology to deeply develop high-end ophthalmic medical devices in China, allowing Chinese innovation to genuinely benefit eye patients worldwide and improve patients' quality of life! Simedice has an experienced core technical team; the heads of R&D and production have over a decade of relevant experience in leading multinational companies in the industry overseas, possess profound qualifications, and hold numerous patents; the management personnel have more than ten years of international management experience in large multinational pharmaceutical groups overseas; core team members in R&D, production, and quality management all have at least five years of work experience in this field. The company employs internationally leading R&D, production, and testing equipment, focusing on the R&D and production of high-end intraocular lens series products and advanced ophthalmic equipment, providing high-quality product services for every ophthalmic patient. The company embraces an innovative, enterprising, collaborative, and caring corporate culture, advocating the core concept of "technological innovation, quality first, aggressive progress, and sustainable development," striving to become a leader in high-end ophthalmic medical devices.